Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation (NYSE: WAT), a global leader in analytical instrumentation and laboratory technologies, provides critical solutions for pharmaceutical development, food safety testing, and environmental monitoring. This dedicated news hub aggregates official announcements, financial disclosures, and strategic updates directly impacting the company's market position and technological advancements.
Investors and industry professionals will find curated updates including quarterly earnings reports, product innovation announcements, executive leadership changes, and regulatory developments. Our repository ensures timely access to filings, partnership agreements, and scientific breakthroughs related to Waters' chromatography systems, mass spectrometry platforms, and thermal analysis instruments.
Key content categories include financial performance updates, new product launches, research collaborations, and operational expansions. Bookmark this page to monitor developments affecting Waters' role in life sciences R&D, quality assurance protocols, and laboratory informatics solutions across 100+ countries.
Waters Corporation (NYSE:WAT) has appointed Dan Brennan and Mark Vergnano to its Board of Directors, effective November 23, 2022. Brennan, currently CFO at Boston Scientific, and Vergnano, former CEO of The Chemours Company, bring extensive experience crucial for Waters' growth strategy. Their addition follows a robust board refreshment process, making the board nine members strong, with eight independent. Chairman Dr. Flemming Ornskov highlights their potential to enhance operational and financial expertise as Waters implements its growth initiatives.
Waters Corporation has launched a new PFAS quantitation workflow that simplifies the detection of Per- and Polyfluoroalkyl Substances (PFAS) in various environmental samples. This end-to-end solution can measure parts-per-quadrillion (ppq) levels, exceeding regulatory limits, and includes automated data processing through the waters_connect software. This innovation aims to streamline laboratory operations while reducing manual errors in PFAS measurement, addressing increasing regulatory requirements.
Waters Corporation (NYSE:WAT) will participate in the Evercore ISI HealthconX Conference on November 29th, 2022. Udit Batra, Ph.D., the President and CEO, will engage in a virtual fireside chat from 1:00-1:45 PM EST. Investors can access the live webcast on the company's investor relations website and a replay will be available for 30 days.
Waters is a global leader in analytical instruments and software, with over 7,800 employees and operations in over 35 countries, specializing in chromatography and mass spectrometry.
Waters Corporation (NYSE: WAT) reported Q3 2022 sales of $709 million, reflecting a 7% increase as reported and 15% in constant currency. Key highlights include a 21% surge in instrument sales and strong revenue growth across all major geographies, particularly a 23% increase in China. Recurring revenues rose 10% in constant currency. GAAP EPS remained stable at $2.60, while non-GAAP EPS slightly declined to $2.64. Waters raised its full-year 2022 sales growth guidance to 11.5%-12%, despite a 6% unfavorable currency impact. For Q4, it projects sales growth of 6%-8% and non-GAAP EPS of $3.66-$3.76, factoring in currency headwinds.
Waters Corporation has launched the Extraction+ Connected Device, which automates solid phase extraction (SPE) methods, significantly reducing sample preparation time by up to four hours per sample set. This innovation, compatible with the Andrew+ Pipetting Robot and controlled through OneLab Software, minimizes user variability and enhances assay reproducibility. The device is now available globally, marking a step forward in laboratory efficiency for biological, food, forensic, and environmental applications.
Waters Corporation (NYSE:WAT) announced a multi-year investment of up to €6 million, supported by IDA Ireland, to enhance its research and development operations in Wexford, Ireland. This expansion aims to create new scientific jobs and focus on clinical diagnostic solutions. Waters commemorates its 25th anniversary in Ireland, reinforcing its commitment to advancing mass spectrometry technologies for early disease detection. The Wexford facility is vital for manufacturing in-vitro diagnostic systems and aims to improve diagnostic accuracy for various medical conditions.
Waters Corporation (NYSE:WAT) will announce its Q3 2022 financial results in a conference call on November 1, 2022, at 8:00 a.m. ET. The presentation will be accessible through a live webcast on Waters’ investor relations website. A replay option will be available until November 15, 2022, at midnight ET. Waters Corporation has over 60 years of experience in analytical instruments and software, serving various sectors, including life sciences and materials, with a workforce of more than 7,800 employees.
Waters Corporation (NYSE:WAT) has launched advanced powder rheology capabilities for its HR Rheometer, enhancing its versatility in characterizing liquids, solids, and powders. The new SmartSwap™ tooling allows quick transitions between liquid and powder measurements in just 10 seconds, improving sample preparation speed by three times compared to competitors. This innovative technology supports industries like lithium-ion batteries and pharmaceuticals, ensuring accurate data for optimizing materials and processing. The powder rheology accessory is available for existing or new HR Rheometers.